Immatics N.V. is a clinical-stage biopharmaceutical company focused on developing PRAME-directed immunotherapies for patients with cancer. The company’s pipeline includes T-cell receptor (TCR) T-cell therapies and bispecific T-cell engaging receptors (TCERs) targeting the PRAME protein, which is expressed in various solid tumors. Key product candidates include anzu-cel (anzutresgene autoleucel), a one-time infusion cell therapy for advanced melanoma, and IMA402, an off-the-shelf bispecific therapy. Immatics also develops combination therapies, such as anzu-cel with Moderna’s mRNA-4203, and IMA402 with IMA401 for non-small cell lung cancer. The company operates as a transatlantic organization with sites in Germany and the United States, serving markets in the U.S. and the EU5. Founded in 2000 as a spin-out from the University of Tübingen, Immatics was incorporated as Immatics B.V. in 2020 to effectuate a business combination with ARYA Sciences Acquisition Corp. before converting to Immatics N.V.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage immatics.com
Sector Healthcare IR page investors.immatics.com/press-releases
Tags
oncology, adoptive cell therapy, bispecific antibodies, t-cell receptor therapy, melanoma, immunotherapy, precision medicine, solid tumors, anzu-cel, anzutresgene autoleucel, IMA203, IMA203CD8, IMA402, IMA401, ACTengine, TCER, Immatics Biotechnologies GmbH, Immatics US Inc., mRNA-4203, SUPRAME
Press page —

Metrics

Valuation  
Market cap $ 1.074B
Market cap (USD) $ 1.074B
P/E -4.86
PEG —
P/BV 2.37
P/S 19.60
P/OCF -4.60
P/FCF -4.51
Dividend yield —
Turnover / mcap —
Returns  
ROE -37.1%
ROI -130.0%
ROIC -90.4%
Profit margin -407.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 44
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 48.266M 155.835M 53.997M 172.831M 34.763M — —
Net profit -196.447M 15.218M -96.994M 37.514M -93.335M -229.059M -31.571M
Free cash flow -183.184M -174.302M -12.571M 94.393M -86.89M -93.03M 68.824M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 8.93 6.47 9.67 8.65 11.4 9.23 —
Price performance 12m 0.48 -0.32 0.21 -0.35 0.25 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (EUR) 34M 40.1M 67.1M 87.6M 107M 119M 148M 184M
↳ 5y CAGR +28.4% +29.9% +22.3%
Reported Mar 30, 2021 Mar 30, 2021 Mar 30, 2021 Mar 23, 2022 Mar 22, 2023 Mar 21, 2024 Mar 27, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Immatics Announces Third Quarter 2026 Bull 4 Bear 3 Results

Financial Results and Business Update

•Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint

•SUPRAME topline data disclosure remains expected in H1 2027, followed by BLA submission in 2027

•IMA203CD8 PRAME Cell Therapy: Updated Phase 1 data presented at ESMO Congress 2026 showed deep and durable anti-tumor activity across multiple tumor types and a manageable safety profile; in gynecologic cancers at clinically relevant doses, cORR was 55% and mDOR was 8.4 months

•IMA402 PRAME Bispecific: Phase 1b data presented at ESMO Congress 2026 continue to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profile, within the recommended Phase 2 dose (RP2D) range.

· IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profile

· IMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate of 91% in advanced melanoma patients with high PRAME expression

· Clinical profile of IMA402 reinforces development path across multiple solid tumor indications, including melanoma, gynecologic cancers and lung cancer, in earlier and later treatment lines, supported by Immatics’ innovative, rapid liquid biopsy-based PRAME testing

· IMA203CD8 PRAME cell therapy demonstrated deep and durable anti-tumor activity across multiple tumor types with a manageable safety profile, supporting its tumor-agnostic potential. At clinically relevant dose levels in patients with advanced, heavily pretreated gynecologic cancers, cORR was 55% with a median DOR of 8.4 months

Houston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V.

Immatics N.V. — Announcement (Form 6-K) Bull 5 Bear 0 Clinical/regulatory

Targeting PRAME+ Tumors with IMA203CD8, a PRAME - directed TCR T - cell Therapy: Results from a Phase 1 Study Antonia Busse 1 , Dejka M. Araujo 2 , Winfried Alsdorf 3 , Oladapo Yeku 4 , Tobias A.W. Holderried 5,6 , Leonel F. Hernandez - Aya 7 , Sarah Taylor 8 , Dirk Jaeger 9 , Manik Chatterjee 10 , Anthony J. Olszanski¹¹, Eva M. Wagner - Drouet¹², Peter Herhaus¹³, Katrin Wetzko 14 , Apostolia M. Tsimberidou², Friederike Schmitz 5 , Diwakar Davar 15 , Karine Pozo 16 , Liane Preussner 17 , Cedrik M. Britten 17 , Martin Wermke 18 Prof. Dr. med. Antonia Busse Proffered paper presentation , abstract #7231 1 Charité Medical University Hospital, Berlin, Germany; 2 The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3 Department of Hematology and Oncology , University Hospital Hamburg Eppendorf, Hamburg, Germany; 4 Massachusetts General Hospital, Boston, MA, USA; 5 University of Bonn, University Hospital Bonn, Medical Clinic and Polyclinic III Internal Medicine with a focus on Oncology , Hematology , and Rheumatology , Bonn, Germany; 6 Clinical Division of Hematology , Department of Internal Medicine, Medical University of Graz, Graz, Austria; 7 University of Miami, Miami,

Prompts

Immatics N.V. (ticker IMTX), listed in United States.

ETFs Holding Immatics N.V.

ETF Weight in ETF Shares Market value As of
TMED 0.87% 19,722 $ 199.784K Jun 30, 2026
CANC 0.81% 179,617 $ 1.712M Aug 31, 2026